Pages that link to "Q39261395"
Jump to navigation
Jump to search
The following pages link to Nerve Growth Factor and Pain Mechanisms (Q39261395):
Displaying 32 items.
- Functional and Molecular Characterization of Mechanoinsensitive "Silent" Nociceptors (Q47099480) (← links)
- Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain (Q47717163) (← links)
- What is new in pain modification in osteoarthritis? (Q48526597) (← links)
- NaV1.9 Potentiates Oxidized Phospholipid-Induced TRP Responses Only under Inflammatory Conditions. (Q49577397) (← links)
- Peripheral Mechanisms Contributing to Osteoarthritis Pain. (Q52685598) (← links)
- Fast Green FCF Alleviates Pain Hypersensitivity and Down-Regulates the Levels of Spinal P2X4 Expression and Pro-inflammatory Cytokines in a Rodent Inflammatory Pain Model. (Q55027191) (← links)
- [EXPRESS] A third HSAN5 mutation disrupts the Nerve Growth Factor furin cleavage site (Q57295301) (← links)
- Mechanisms that drive bone pain across the lifespan (Q57790366) (← links)
- Mechanisms Underlying Bone and Joint Pain (Q58102355) (← links)
- [EXPRESS] Differential modulation of voltage-gated sodium channels by nerve growth factor in three major subsets of TrkA-expressing nociceptors (Q58617465) (← links)
- Is IL-1β Further Evidence for the Role of in Degenerative Disc Disease? Lessons From the Study of the Inflammatory Skin Condition Acne Vulgaris (Q58781062) (← links)
- Interaction of Nerve Growth Factor β with Adiponectin and SPARC Oppositely Modulates its Biological Activity (Q64112555) (← links)
- Nociceptor Signalling through ion Channel Regulation via GPCRs. (Q64923978) (← links)
- The beta-adrenergic receptor agonist, terbutaline, reduces UVB-induced mechanical sensitization in humans (Q89467945) (← links)
- Anti-nerve growth factor does not change physical activity in normal young or aging mice but does increase activity in mice with skeletal pain (Q89562296) (← links)
- Osteoarthritis pain: What are we learning from animal models? (Q90222490) (← links)
- Antibodies to watch in 2019 (Q90270674) (← links)
- [Inflammation and osteoarthritis-related pain] (Q90602605) (← links)
- Understanding the genetic basis of congenital insensitivity to pain (Q90702055) (← links)
- An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis (Q90707220) (← links)
- Therapeutic options for targeting inflammatory osteoarthritis pain (Q91865193) (← links)
- Composite Pain Biomarker Signatures for Objective Assessment and Effective Treatment (Q92192309) (← links)
- Pain and immunity: implications for host defence (Q92384478) (← links)
- Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety (Q92400214) (← links)
- Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review (Q92422137) (← links)
- Update on novel pharmacological therapies for osteoarthritis (Q92434466) (← links)
- Developing Modern Pain Therapies (Q92535035) (← links)
- Tumour innervation and neurosignalling in prostate cancer (Q92643919) (← links)
- The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial (Q92808933) (← links)
- Nerves in cancer (Q92890751) (← links)
- Local anaesthesia decreases nerve growth factor induced masseter hyperalgesia (Q99608423) (← links)
- Nerve growth factor in the equine joint (Q104615240) (← links)